Clinical Trial Protocol
Iranian Registry of Clinical Trials

10 Jul 2026

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Protocol summary

Summary
Purpose: to evaluate the efficacy and safety of itravitreal bevacizumab in proliferative diabetic retinopathy (PDR)patients. Design: Quasi clinical study Methods: 39 eyes of 26 PDR patients were evaluated. All patients completed 12 weeks of follow-up. Patients were treated with one intravitreal injection of 1.25 mg of bevacizumab. Evaluation consisted of a complete ophthalmologic examination, including Snellen Visual acuity (VA) measurement, ophtalmoscopy and fluorescein angiography(FA). Main outcome measures: changes in VA and FA.

General information

Acronym
IRCT registration information
IRCT registration number: **IRCT138903314232N1**
Registration date: **2010-11-26, 1389/09/05**
Registration timing: **retrospective**

Last update:
Update count: **0**
Registration date
2010-11-26, 1389/09/05

Registrant information
Name
Ebrahim Mikaniki
Name of organization / entity
Babol University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 11 1219 9015
Email address
e.mikaniki@mubabol.ac.ir

Recruitment status
Recruitment complete
Funding source
Vice chancellor for research, Babol University of Medical Sciences

Expected recruitment start date
2007-10-31, 1386/08/09
Expected recruitment end date
2009-10-31, 1388/08/09
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Public title
Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathy
Purpose
Treatment
Inclusion/Exclusion criteria
Patients were not offered treatment if they had uncontrolled hypertension or recent myocardial infarction or cerebral vascular accident.
Age
From **35 years** old to **70 years** old
Gender
Both

Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **39**
Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Babol university of medical sciences

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Approval date

2010-10-12, 1389/07/20

Ethics committee reference number

1816

Health conditions studied

1

Description of health condition studied

diabetic retinopathy

ICD-10 code

H36.0

ICD-10 code description

Retinal disorders in diseases classified elsewhere

Primary outcomes

1

Description

Visual Acuity

Timepoint

0, 4, 12 weeks

Method of measurement

complete ophtalmic examination

Secondary outcomes

1

Description

Speed of improvement and durability of visual acuity

Timepoint

4 and 12 weeks after intervention

Method of measurement

ophtalmic examination

Intervention groups

1

Description

One intravitreal injection of 1.25 mg of bevacizumab (Avastin)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Beheshti Hospital

Full name of responsible person

Dr Mikaniki

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research; Babol university of medical sciences

Full name of responsible person

Vice chancellor for research

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research; Babol university of medical sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty